Literature DB >> 24633991

Longer survival in patients with human papillomavirus-related head and neck cancer after positive postradiation planned neck dissection.

Shao Hui Huang1, Samip Patel2, Brian O'Sullivan1,2, Xiaowei Shen3, Wei Xu3, Ilan Weinreb4, Bayardo Perez-Ordonez4, Jonathan Irish2, John Waldron1,2, Patrick Gullane2, Ralph Gilbert2, Dale Brown2, John Kim1, Jeremy Freeman2, John R de Almeida2, David Goldstein2.   

Abstract

BACKGROUND: The purpose of this study was to compare outcomes between human papillomavirus (HPV)-related versus -unrelated head and neck cancer after pathological positive planned neck dissection.
METHODS: Positive planned neck dissection for head and neck cancers from 1998 to 2010 were included in this study. Outcomes after planned neck dissection were compared between HPV-related versus -unrelated cohorts. Multivariate analysis identified survival predictors.
RESULTS: HPV-related head and neck cancer (n = 32) had better 5-year overall survival (48% vs 27%; p = .021), marginally lower second malignancy (7% vs 16%; p = .13), but similar local, regional, and distant control (87% vs 89%; 94% vs 89%; 62% vs 58%, respectively) versus HPV unrelated (n = 38). HPV status conferred reduced risk of death (hazard ratio [HR], 0.5; p = .038) after adjusting for age, smoking, and initial T and N classifications.
CONCLUSION: This study reveals that positive planned neck dissection for HPV-related head and neck cancer represents a biologic unfavorable subset of the HPV population with unsatisfactory survival attributable to distant metastasis. The longer survival compared to the HPV-unrelated counterpart is likely related to a marginally lower second malignancy rather than better disease control.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  head and neck cancer; human papillomavirus; planned neck dissection; radiotherapy; survival

Mesh:

Year:  2014        PMID: 24633991     DOI: 10.1002/hed.23690

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

1.  Predictive Factors for Prophylactic Percutaneous Endoscopic Gastrostomy (PEG) Tube Placement and Use in Head and Neck Patients Following Intensity-Modulated Radiation Therapy (IMRT) Treatment: Concordance, Discrepancies, and the Role of Gabapentin.

Authors:  Wuyang Yang; Todd R McNutt; Sara A Dudley; Rachit Kumar; Heather M Starmer; Christine G Gourin; Joseph A Moore; Kimberly Evans; Mysha Allen; Nishant Agrawal; Jeremy D Richmon; Christine H Chung; Harry Quon
Journal:  Dysphagia       Date:  2016-01-11       Impact factor: 3.438

2.  p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status.

Authors:  Jeremy Shelton; Bibianna M Purgina; Nicole A Cipriani; William D Dupont; Dale Plummer; James S Lewis
Journal:  Mod Pathol       Date:  2017-06-16       Impact factor: 7.842

3.  Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129.

Authors:  Thomas J Galloway; Qiang Ed Zhang; Phuc Felix Nguyen-Tan; David I Rosenthal; Denis Soulieres; André Fortin; Craig L Silverman; Megan E Daly; John A Ridge; J Alexander Hammond; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-05-28       Impact factor: 7.038

4.  No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression.

Authors:  R Maquieira; S K Haerle; G F Huber; A Soltermann; S R Haile; S J Stoeckli; Martina A Broglie
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-10       Impact factor: 2.503

5.  p16 Immunohistochemistry in Oropharyngeal Squamous Cell Carcinoma Using the E6H4 Antibody Clone: A Technical Method Study for Optimal Dilution.

Authors:  James S Lewis; Jeremy Shelton; Krystle Lang Kuhs; Derek K Smith
Journal:  Head Neck Pathol       Date:  2017-11-30

6.  Prediction of concurrent chemoradiotherapy outcome in advanced oropharyngeal cancer.

Authors:  Masahiro Hasegawa; Hiroyuki Maeda; Zeyi Deng; Asanori Kiyuna; Akira Ganaha; Yukashi Yamashita; Sen Matayoshi; Shinya Agena; Takafumi Toita; Takayuki Uehara; Mikio Suzuki
Journal:  Int J Oncol       Date:  2014-06-18       Impact factor: 5.650

7.  The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies.

Authors:  Małgorzata Wierzbicka; Krzysztof Szyfter; Piotr Milecki; Krzysztof Składowski; Rodryg Ramlau
Journal:  Contemp Oncol (Pozn)       Date:  2015-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.